Welcome to our dedicated page for Bullfrog AI Holdings news (Ticker: BFRGW), a resource for investors and traders seeking the latest updates and insights on Bullfrog AI Holdings stock.
BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) generates news at the intersection of artificial intelligence, bioinformatics, and pharmaceutical development. This page aggregates coverage related to the company’s AI-driven platforms for drug discovery and clinical trial optimization, giving readers a focused view of how its technology is being applied and discussed across the life sciences sector.
Company announcements highlight the use of its proprietary bfLEAP ae analytics engine, bfPREP ae data preparation module, and BullFrog Data Networks ae platform in real-world settings. Recent news includes precision-oncology analyses in pancreatic adenocarcinoma, where BullFrog AI reports identifying patient subgroups with an almost threefold increase in mean survival in glufosfamide trial data, as well as an accepted abstract and poster presentation at the ASCO Gastrointestinal Cancers Symposium.
Investors and industry observers can also follow updates on commercial collaborations, such as the company’s work with Eleison Pharmaceuticals on late-stage oncology data and its partnership with Sygnature Discovery to introduce BullFrog Data Networks ae to global biopharma clients. Additional news items cover technical conference presentations, whitepapers on AI in bioinformatics, and webinars that detail how BullFrog AI operationalizes human-in-the-loop AI agents in clinical data workflows.
By reviewing the news feed for BFRG and BFRGW, readers can track developments in BullFrog AI’s scientific validation efforts, commercial initiatives, and regulatory disclosures. This page provides a centralized view of press releases and related articles for those monitoring the company’s role in AI-enabled drug development.
BullFrog AI (NASDAQ: BFRG) reported that its bfLEAP® platform identified treatment-effect heterogeneity and key biomarkers in a post-hoc analysis of the randomized phase 3 trial TH-CR-302, finding an almost threefold increase in mean survival from control to treatment arms in specific pancreatic cancer subgroups.
Findings will be presented at the ASCO GI Symposium on Jan. 9, 2026 (poster B) and will appear in the Journal of Clinical Oncology supplement. The analysis, conducted with Eleison Pharmaceuticals and Moffitt Cancer Center authors, highlights bfLEAP® and bfPREP™ as tools for data-driven patient clustering, early predictor identification, and precision-oncology stratification in glufosfamide development.
BullFrog AI (NASDAQ: BFRG) published its 2025 annual letter highlighting commercialization progress, technology milestones and 2026 catalysts. Key developments include a signed commercial collaboration with Sygnature Discovery expected to generate significant revenue through 2028, a real-world deployment with Eleison Pharmaceuticals in a pivotal Phase 3 oncology program, and the launch of bfPREP, an AI data‑preparation module that the company says can reduce data prep timelines from months to days. The company reports an annual burn of approximately $6.2 million and has financing flexibility via a $10 million equity line and an ATM. Near-term catalysts include the public presentation of Eleison results at ASCO on January 9, 2026 and ongoing advanced discussions with large pharmaceutical partners.
BullFrog AI (NASDAQ: BFRG) published a whitepaper on Nov 18, 2025 titled “AI in Bioinformatics: Turning Complex Data into Actionable Insights with BullFrog Data Networks.”
The paper describes how bfLEAP and BullFrog Data Networks address three bioinformatics pitfalls: the compositional data trap, misleading feature importance, and generative AI overreach. It highlights causal inference and probabilistic validation to generate reproducible insights across genomics, transcriptomics, proteomics, and clinical data for target ID, biomarker discovery, and patient stratification.
BullFrog AI (NASDAQ: BFRG) will present a technical talk titled "Human-in-the-Loop Agent Workflows with bfPREP™" at the AI Drug Discovery & Development Summit 2025 in Boston, November 18–20, 2025.
The presentation is part of Technical Insights Session 1 on Wednesday, November 19, 2025 and will describe how bfPREP™ operationalizes AI agents for reliable, reproducible data preparation in drug development, including structured outputs, stable schemas, and human validation. bfPREP™ is BullFrog AI’s data cleansing and preparation module within BullFrog Data Networks™, focused on clinical, omics, and real-world data.
The summit expects 500+ attendees and 100+ speakers and targets AI applications across discovery through clinical development.
BullFrog AI (NASDAQ: BFRG) announced an abstract accepted for presentation at the 2026 ASCO Gastrointestinal Cancers Symposium, Jan 8–10, 2026 in San Francisco.
The poster, titled “Data-driven subtyping and differential glufosfamide benefit in pancreatic adenocarcinoma,” will be presented in Poster Session B on January 9, 2026 and published in the ASCO GI online proceedings and the Journal of Clinical Oncology supplement. The study, co-authored with Eleison Pharmaceuticals and investigators at Moffitt Cancer Center, uses BullFrog AI’s bfLEAP and bfPREP platforms to identify patient subtypes with potential enhanced response to glufosfamide.
BullFrog AI (NASDAQ: BFRG) will host an exclusive live investor webinar and Q&A on October 30, 2025 at 4:15 p.m. ET, presented by RedChip Companies and led by founder and CEO Vin Singh. The presentation will cover BullFrog AI’s AI-driven drug discovery platforms, including the BullFrog Data Networks™ Solutions Library powered by the proprietary bfLEAP™ causal AI engine and the newly launched bfPREP™ module for automated data cleansing and standardization.
The company will discuss its scalable, plug-and-play toolkit for the drug development lifecycle and strategic global collaborations, including a partnership with CRO Sygnature Discovery, which the release says is expected to expand commercial reach and drive significant revenue growth. A live Q&A will follow; registration is free at the listed RedChip webinar link.
BullFrog AI (NASDAQ: BFRG) announced the expansion of its internal sales organization to accelerate the commercialization of its clinical trial optimization solutions, including the recently launched bfPREP™ module. This expansion complements their existing partnership with Sygnature Discovery for BullFrog Data Networks™.
The dual-pronged commercial strategy includes: 1) Sygnature partnership focusing on selling target selection solutions to global biopharma clients, and 2) Direct sales team marketing bfPREP and clinical trial optimization tools. The bfPREP module, initially developed for Eleison Pharmaceuticals collaboration, standardizes diverse clinical trial data into analyzable formats within days.
BullFrog AI (NASDAQ: BFRG) has officially launched commercial sales of its BullFrog Data Networks™ platform through its partnership with Sygnature Discovery. The launch, which began on September 12, represents a potential $15-30 million revenue opportunity through 2028.
The AI-driven platform, designed for drug development and discovery, will be marketed to Sygnature's global biopharma client base. The platform's capabilities include target identification, mechanism-of-action analysis, patient stratification, drug repurposing, and clinical trial optimization. Sygnature's business development team has completed training to integrate BullFrog Data Networks™ into their drug discovery solutions portfolio.
BullFrog AI (NASDAQ: BFRG), a technology-enabled drug development company, will host a webinar on October 6, 2025 titled "Clinical Data Analysis with Agents: Reliable Automation with Human Oversight." The company's Director of AI, Dr. Juan Felipe Beltrán, will showcase how BullFrog's proprietary platforms bfPREP™ and bfLEAP™ transformed over 10,000 pages of unstructured clinical PDFs into OMOP-structured datasets.
The presentation will demonstrate how BullFrog AI combines automated processing with human oversight to ensure data integrity in clinical research workflows. The webinar will focus on practical applications of their technology for parsing clinical documents, standardizing medical vocabularies, and implementing template-driven agents for data transformation.
BullFrog AI (NASDAQ: BFRG) reported significant progress in its collaboration with Eleison Pharmaceuticals, showcasing the capabilities of its AI platforms bfPREP™ and bfLEAP®. The company successfully developed a new data ingestion module that converted over 10,000 pages of clinical trial PDFs into standardized datasets.
The collaboration demonstrated BullFrog AI's ability to handle complex clinical documentation through its enterprise-grade platforms. The bfPREP™ module, which emerged as a standalone commercial offering, transforms legacy clinical trial data into structured, actionable insights. The bfLEAP® analytics engine identified data-driven patient subgroups to enhance trial design and market positioning.
Following this success, both companies are preparing a joint scientific submission for an upcoming oncology conference and are discussing a potential second collaboration contract.
FAQ
What is the current stock price of Bullfrog AI Holdings (BFRGW)?
